What the research found
Researchers examined electronic health records from a large integrated healthcare system to build a snapshot of nearly 300,000 adults with obesity. The group was predominantly female (63%), racially diverse (27% Black), and nearly half lived in neighbourhoods with high social vulnerability—meaning limited access to resources, lower income, or other structural barriers to health. About half had class I obesity (BMI 30–34.9), with the remainder in higher categories.
The study revealed two striking patterns. First, there were substantial gaps in routine screening: over 40% of patients lacked recent HbA1c or cholesterol measurements despite obesity and high rates of diabetes and hypertension. Second, GLP-1 agonists have been adopted rapidly—18% of the entire cohort received a GLP-1 prescription for weight management within two years, and 22% received any weight loss medication. Common comorbidities included hypertension, type 2 diabetes, depression, and anxiety.
Why it matters for you
If you're using MyKine to track metabolic markers and optimise body composition, this data illustrates why your diligence matters. Most people with obesity in this health system weren't getting regular HbA1c or lipid panels—the very biomarkers you likely monitor. This screening gap means many are missing early signals of metabolic dysfunction or cardiometabolic risk, even when they're actively engaged in healthcare.
The high uptake of GLP-1 agonists also reflects a genuine shift in clinical practice. If you're considering or using these drugs, you're part of a real trend, not an outlier. The cohort's high representation of women and socially vulnerable populations suggests that weight management—and access to novel pharmacotherapy—remains unequally distributed. For MyKine users, this underscores the value of tracking HbA1c, lipids, blood pressure, and inflammatory markers alongside weight and body composition, especially if you're using peptides or other interventions that affect glucose metabolism.
Caveats
- Observational and cross-sectional: describes what happened, not why or what outcomes followed
- Single health system: findings may not generalise to populations with different healthcare access, geography, or demographics
- Screening gaps may reflect documentation rather than clinical practice: some tests may have occurred but weren't recorded in the EHR
- No data on efficacy or adherence: the 18% GLP-1 prescription rate doesn't indicate how many continued the drug or achieved weight loss
- No comparison group: can't assess whether screening gaps or comorbidities differ from populations without obesity